Recent advantages in targeted drugs delivery system: A focus on nanotechnology and its application in Pharmacology

Deepshikha[1st], Supriya Kashyap[2nd], Sonu[3rd], Jaspreet Chauhan[4th], Geetanjali Sinha[5th], Sanchit Sharma[6th]

Corresponding author - Supriya Kashyap
deepshikha20012003@gmail.com[1st],supriyakashyap1324@gmail.com[2nd],
Sonu.19177@rayatbahrauniversity.edu.in[3rd],jasschauhan2004@gmail.com[4th],
geetanjalisinha777@gmail.com[5th], sharmasanchit0013@gmail.com[6th]

B Pharmacy Candidate[1,4,5,6], University school of Pharmaceutical Sciences (Rayat Bahra University, Mohali Punjab)
Assistant Professor [2,3], University school of Pharmaceutical Sciences (Rayat Bahra University, Mohali Punjab)

Abstract

Targeted drug delivery system (TDDS) developments are significantly responsible for the revolutionary change in pharmacology. By guaranteeing that pharmaceuticals are administered directly to particular places in the body, these systems minimize systemic adverse effects and improve the safety, effectiveness, and precision of medications. This progress has been greatly aided by the incorporation of nanotechnology, which provides new techniques for precisely targeting cells or tissues. TDDS systems are essential for treating a range of complex ailments, such as cancer, neurological disorders, and infectious diseases, since they make it possible for medications to more efficiently reach their intended targets through the use of nanoparticles and other nanocarriers. By addressing conventional obstacles such low bioavailability, restricted solubility, and quick drug removal from the body, nanotechnology in pharmacology aims to increase the selectivity and effectiveness of medication administration. medications' solubility and stability are improved by nanoparticle engineering, which guarantees that the medications will stay whole and functioning until they reach their intended location. Targeted distribution of chemotherapeutic medicines can decrease the negative side effects frequently associated with conventional therapies and prevent collateral harm to healthy tissues, making this capability especially advantageous in cancer therapy. The utilization of certain drug targeting mechanisms, such as active targeting (by attaching targeting ligands or antibodies to nanoparticles) and passive targeting (by increasing permeability and retention effect), is one of the main components of TDDS. By precisely localizing therapeutic medicines, these techniques maximize their concentration at the illness site while reducing their exposure to healthy tissues. For instance, TDDS can help deliver genes or medications directly to the brain or tumor cells, providing a more effective and less harmful option than conventional methods in gene therapy and neurological treatments where accuracy is essential. The versatility of TDDS is further

increased by the range of nanoparticle carriers, including liposomes, dendrimers, micelles, and polymeric nanoparticles. These carriers can be made to regulate a drug's release profile, enabling targeted or sustained release over long periods of time. This feature helps lower the frequency of delivery while also optimizing the drug's pharmacokinetics, which can enhance patient compliance and quality of life.
While TDDS offers significant benefits, challenges remain, including the potential for toxicity, the complexity of production, and regulatory hurdles. Nevertheless, the continuous advancements in nanotechnology hold immense promise for the future of pharmacology.

Graphical Abstract

1. Introduction

1.1 Overview of Systems for Drug Delivery

Drug delivery systems (DDS) are crucial in pharmacology because they allow therapeutically active substances to be delivered in a regulated way to the intended site of action. Oral, intravenous, and other systemic administration are the mainstays of traditional drug delivery techniques, which might have adverse effects on healthy tissues in addition to the target area. Additionally, the substance may be digested or removed before it reaches its target location, making these techniques potentially ineffective.

As contemporary medicine has advanced, there has been a growing demand for targeted drug delivery systems (TDDS), which transport medications precisely to the site of disease in an effort to increase therapeutic efficacy, decrease adverse effects, and improve drug bioavailability.

1.2 What is Drug Delivery That Is Targeted?

The deliberate creation of pharmacological formulations that can localize a medication to its location of action—typically a sick tissue or particular organ—is known as targeted drug delivery. TDDS decreases the necessary dosage and minimizes off-target effects by guaranteeing that the medicine is administered exactly where it is needed.

TDDS can be divided into two primary categories: active targeting, which involves delivering medications by binding to certain receptors on target cells under the guidance of ligands, and passive targeting, which involves employing nanoparticles to take advantage of the inherent characteristics of tissues like tumors.

1.3 Nanotechnology's Function in Drug Delivery

A key component in the creation of TDDS is nanotechnology. Usually between 1 and 1000 nanometers in size, nanoparticles have special physical, chemical, and biological characteristics that make them perfect for drug delivery. These characteristics include the capacity to alter their surface characteristics to enhance stability, targeted specificity, and controlled release, as well as a high surface area-to-volume ratio that permits the loading of large quantities of medications. Numerous drawbacks of conventional drug delivery techniques may be addressed by nanotechnology.

2. Drug Delivery Using Nanotechnology



2.1 Different Types of Nanocarriers

Drugs are transported via nanocarriers, which are made to control release, improve targeting, and shield the medication from premature destruction. Among the most widely utilized kinds of nanocarriers are: Nanoparticles are solid colloidal particles composed of metals, polymers, or lipids. They can be designed to offer controlled release and encapsulate medications.

Liposomes: These spherical vesicles can contain both hydrophilic and hydrophobic medications due to their lipid bilayer structure. They are frequently used for drug administration because of their biocompatibility.

Micelles: Made of surfactant molecules, these self-assembled structures have the capacity to solubilize hydrophobic medications and increase their bioavailability.

Highly branching macromolecules known as **dendrimers** can be made to attach to their surface or carry medications inside of them.

Hollow cylinders composed of carbon atoms are known as **carbon nanotubes**, or CNTs. Their special structure makes it possible to encapsulate and transport drugs.

Nanogels: These three-dimensional, hydrophilic networks of polymers inflate when submerged in water. The advantage of customizable release profiles is that they can load a wide range of medications.

2.2 Nanotechnology-Based Targeted Drug Delivery Mechanisms

Passive targeting and active targeting are the two main methods of targeted medicine delivery made possible by nanotechnology.

Passive Targeting: This tactic makes use of the biological characteristics that nanoparticles naturally possess. For instance, nanoparticles are used in tumor therapy to take advantage of the enhanced permeability and retention (EPR) effect, which occurs when tiny particles build up in tumor tissue as a result of the tumor's characteristic leaky vasculature. Modifying the surface of nanoparticles to incorporate ligands that can selectively bind to target cell receptors is known as active targeting. These ligands can be tiny compounds, peptides, or antibodies that are intended to target sick tissues or cells, like cancer cells that express particular biomarkers.

2.3 Nanocarriers That Respond to Stimuli

The creation of stimuli-responsive nanocarriers is another exciting discovery in nanotechnology. Only in the proper circumstances do these carriers release their medicinal payload in response to particular internal or external stimuli, such as pH, temperature, light, or magnetic fields. By guaranteeing that medications are only delivered when and where they are required, this method further improves the accuracy of drug administration.

3. Using Nanotechnology for Targeted Medication Administration

Nanotechnology has demonstrated enormous potential in a number of therapeutic domains. Some of the most significant uses in the field of pharmacology are listed below:

3.1 Cancer Treatment

By facilitating the targeted delivery of chemotherapeutic drugs straight to tumor cells, nanotechnology has completely changed the way that cancer is treated. Both healthy and malignant cells are impacted by traditional chemotherapy, which has serious adverse effects. By minimizing harm to healthy tissues, nanocarriers such as liposomes and polymeric nanoparticles might improve the specificity of anticancer medications. Liposomes, including Doxil (liposomal doxorubicin), have shown promise in improving drug delivery to malignancies. Potential uses for gold nanoparticles and carbon nanotubes include medicine delivery and even photothermal therapy, in which the nanoparticles absorb light and transform it into heat to kill cancer cells.

3.2 Delivery of Nucleic Acids and Gene Therapy

By adding, deleting, or changing genetic material in a patient's cells, gene therapy seeks to treat illnesses. Because they may shield genetic material (such as DNA and RNA) and make it easier to move across biological barriers, nanoparticles have become essential instruments in gene delivery.With important ramifications for therapies like CRISPR gene editing, lipoplexes and polyplexes are nanocarriers that safely and effectively carry DNA or RNA.

3.3 Disorders of the Central Nervous System (CNS)

Since most medications cannot pass across the blood-brain barrier (BBB), getting medications to the brain is one of the biggest problems facing modern medicine. Nanotechnology has made it possible to get around this obstacle. Solid lipid nanoparticles and liposomes have been used to transport medications across the blood-brain barrier to treat neurological conditions like Parkinson's and Alzheimer's.

3.4 Vaccines and Infectious Diseases

Additionally, nanoparticles are essential in the battle against infectious diseases. By delivering antibiotics and antivirals precisely, they maximize medication efficacy while reducing adverse effects. Furthermore, the use of nanoparticles in vaccine formulations is growing. Lipid nanoparticles (LNPs) were crucial in the effective creation and administration of mRNA vaccines, such as those for COVID-19 (Pfizer and Moderna).

4. Recent Advancements in Nanotechnology for Targeted Drug Delivery

4.1 Innovations in Nanomaterials

With novel materials created to enhance medication loading, stability, and release patterns, nanomaterials have seen tremendous advancements in recent years. For instance, hybrid nanoparticles—which combine the advantages of many materials—are becoming more and more well-liked. Among them are: biodegradable polymeric nanoparticles that can be designed to release in particular ways.

An external magnetic field can be used to direct magnetic nanoparticles to a specific location.

4.2 Personalized Medicine and Nanotechnology

Personalized medicine is a strategy in which medical treatment is personalized to the specific characteristics of each patient. This is made possible by nanotechnology, which allows for the delivery of customized medicines depending on lifestyle, environmental, and genetic factors. Patient-specific biomarkers can be found with the aid of nanodiagnostics, and theranostic nanoparticles enable diagnosis and treatment to be done at the same time.

4.3 Clinical Research and FDA Authorizations

Despite its modest pace, the clinical translation of nanomedicines is making steady progress. A number of formulations based on nanocarriers, including liposomal Doxil and the use of albumin-bound nanoparticles for paclitaxel (Abraxane), have previously received FDA approval. The application of nanoparticles is being investigated in ongoing clinical trials in fields like infectious diseases, gene therapy, and cancer immunotherapy.

5. Nanotechnology's Drawbacks and Difficulties in Drug Delivery

Despite the encouraging possibilities, there are still a number of obstacles to the broad use of nanotechnology in medication delivery:

Biological Barriers: Tissue penetration, bioavailability, and immune system clearance are some of the issues that nanoparticles may face.

Toxicity: Long-term toxicity may result from the accumulation of some nanoparticles in organs such the liver and spleen.

Regulatory Obstacles: The laws governing nanomedicines are still being developed. For its wider clinical application, precise safety and effectiveness guidelines must be established.

6.1 Progress in the Science of Materials

Numerous advancements in the creation of nanocarriers are led by materials science. More effective and secure drug delivery systems are being developed as scientists investigate novel materials with improved biocompatibility, stability, and targeting capability. Among the significant developments are:

Biodegradable and Biocompatible Materials: Presently, scientists are working to create nanomaterials that decompose in the body without harming the body or building up over time. Biodegradability is being optimized for materials such as dendrimers, lipid-based nanoparticles, and polymeric micelles.

Smart Nanomaterials: These materials are able to react to particular environmental stimuli, including light, pH, temperature, and enzymes. When and when a medicine is needed, these materials could cause its controlled release. For instance, pH-sensitive nanoparticles are being created to distribute the medication locally and target acidic tumor settings.

Nanostructured Materials: These materials have the potential to improve stability, release kinetics, and drug loading. This includes substances like graphene oxide, carbon nanotubes, and gold nanoparticles that may be able to transport medications to deep-seated cancers or difficult-to-reach areas like the brain.

6.2 Utilizing Technologies for Gene Editing

CRISPR-Cas9 and other gene editing technologies are transforming our understanding of how to treat genetic illnesses and abnormalities. In order to increase the effectiveness of gene editing tool delivery, nanotechnology is essential.

CRISPR and Nanoparticle Systems: To ensure precise genetic alterations, nanoparticles can be designed to convey CRISPR/Cas9 components (such the Cas9 protein and guide RNA) into cells. This may aid in the treatment of viral infections, malignancies, and genetic abnormalities.

RNA-Based Nanocarriers: Because RNA-based therapeutics may alter gene expression, they are showing increasing promise. To increase the therapeutic potential of RNA molecules such as siRNA, mRNA, and antisense oligonucleotides, nanoparticles are essential for transporting them to the target cells.

Gene Therapy for Inherited Diseases: As gene delivery systems have advanced, nanotechnology may offer safer and more effective means of delivering genes that can fix DNA-level genetic mutations, creating new avenues for the treatment of inherited diseases such as muscular dystrophy and cystic fibrosis.

6.3 Developments in Theranostics and Diagnostic Tools

Additionally, nanotechnology has potential for bettering diagnostics as well as medicine delivery. The idea of theranostics, which combines diagnostic and therapeutic properties into one nanocarrier, is gaining traction.

Nanodiagnostics: Biomarkers linked to illnesses like cancer, infections, and neurological conditions can be found using nanoparticles. Nanomedicines can diagnose and cure illnesses at the same time by combining medication delivery systems with diagnostic technologies.

Customized Care: By employing nanodiagnostic devices, medical professionals can identify illness biomarkers early on and employ customized nanocarriers for certain therapies. As a result, treatments may become more accurate and individualized, taking into account each patient's unique genetic and molecular makeup.

Multifunctional Nanocarriers: Theranostic nanoparticles enable real-time tracking of drug distribution and effectiveness by combining drug delivery and diagnostic capabilities. These nanocarriers could guarantee the efficacy of the therapy and offer insightful information during treatment.

6.4 Combining Machine Learning (ML) and Artificial Intelligence (AI)

The discipline of targeted medication delivery is anticipated to make considerable strides with the use of artificial intelligence (AI) and machine learning (ML) into the design and optimization of nanocarriers. These technological advancements can assist:

Optimization of Nanocarrier Design: AI and ML systems are able to anticipate the best nanocarrier designs by analyzing large quantities of data from different tests. Faster development and improvement of nanoparticles suited to particular medications and target cells may result from this.

Drug Discovery: Artificial intelligence (AI)-powered platforms are able to examine chemical structures, find possible therapeutic candidates, and forecast how they will interact with particular nanocarriers. This might hasten the creation of novel nanomedicines.

Drug Delivery Predictive Modeling: Machine learning algorithms can be trained to forecast a drug's physiological response when administered by nanoparticles. This entails being aware of the ways in which nanocarriers interact with cells, as well as their bloodstream stability and target site accessibility.

Personalized medicine: Using a patient's genetic profile, illness biomarkers, and response to treatment, AI and ML can be utilized to create customized nanocarrier-based medicines. By guaranteeing that each patient has the best possible drug delivery method, this might greatly enhance treatment results.

6.5 Difficulties and the Need for Creativity

Although nanotechnology has a lot of potential, there are still a number of obstacles to its widespread use in medicine delivery, such as:

Manufacturing and Scalability: Producing homogeneous nanoparticles on a wide scale is one of the major challenges in nanotechnology. It is challenging to maintain high standards of quality while guaranteeing uniformity in size, surface charge, and drug loading capacity.

Safety and Regulatory Issues: To approve nanomedicines, regulatory bodies require precise rules. Comprehensive safety evaluations must be carried out, taking into account the long-term physiological impacts of nanoparticles.

Production Cost: The accessibility of these treatments may be restricted by the high cost of producing nanocarriers. For broad adoption, innovations that lower production costs will be essential.

Complexity in Patient Monitoring: It can occasionally be difficult to keep an eye on how nanocarriers are affecting patients. To monitor the efficacy and distribution of nanoparticles in real time, more advanced imaging and diagnostic tools might be required.

6.6 Summary Table of Future Directions and Opportunities

Table no.1: Future Directions and Opportunities

Area of Advancement	Opportunities	Challenges
Materials Science	Development of biodegradable, biocompatible, and smart nanomaterials. Materials like dendrimers and liposomes.	Difficulty in achieving uniformity at large scale.
Gene Editing and Delivery	CRISPR-Cas9 delivery using nanoparticles. RNA-based therapies like siRNA and mRNA.	Efficient targeting and avoiding immune responses.
Diagnostic and Theranostic Systems	Integration of diagnostics and therapy in one system (theranostics). Personalized drug delivery based on biomarkers.	Technological integration and cost of development.
Artificial Intelligence (AI) and Machine Learning (ML)	AI-driven design of nanocarriers, predictive	Data security and the need for high-quality data.

	modeling for drug behavior, personalized medicine.	
Manufacturing and Scale-Up	Innovative methods for large-scale production of nanoparticles.	Ensuring consistent quality and high-throughput production.
Regulatory and Safety	Development of safety standards and regulatory frameworks for nanomedicines.	Regulatory uncertainty and long approval timelines.

6.7 Conclusion

Unquestionably, drug delivery has a bright future because nanotechnology is at the forefront of transforming medical care. Drug distribution will undergo a substantial change as the domains of genetics, materials science, artificial intelligence (AI), and diagnostic tools develop further. The development of extremely effective, tailored drug delivery systems made possible by nanotechnology can deliver therapeutic substances with previously unheard-of precision, minimizing adverse effects and improving patients' overall therapeutic results. Personalized medicine is one important area where nanotechnology holds great promise for significant advancements. Drug delivery can be made more precise and efficient by designing nanocarriers to react to certain biomarkers or cellular targets, which is made possible by the expanding capacity to customize therapies to each patient's unique genetic profile. This customized approach has the potential to significantly improve patient outcomes by providing safer, more comfortable, and more effective medicines. Notwithstanding the enormous advancements, there are still obstacles in the way of the broad clinical use of nanomedicines. It is necessary to address issues including the possible toxicity of specific nanoparticles, regulatory barriers, and the difficulties of large-scale manufacture. However, promising answers to these problems might be found in the incorporation of machine learning (ML) and artificial intelligence (AI) into drug development and delivery procedures. AI can help streamline the drug formulation process, forecast how nanocarriers will behave in the body, and optimize their design. Additionally, machine learning algorithms can direct the creation of more individualized and efficient treatment plans and hasten the identification of novel therapeutic targets. New avenues for medication delivery are being made possible by the combination of nanomedicine, artificial intelligence, and other cutting-edge technology. In addition to increasing the accuracy and efficacy of treatments, these technologies will make it possible to create new treatments for illnesses that were previously incurable, such as complex conditions like cancer, neurological disorders, and genetic diseases. In summary, a new era of medicine marked by increased efficacy, safety, and patient-centered care is set to be ushered in by the convergence of nanotechnology, artificial intelligence, and customized medicine.

References

1. Esfandyari-Manesh M, Gholami A, Ghasemi N, et al. Recent advances in nanotechnology-based drug delivery systems for targeted therapy of breast cancer. J Drug Target. 2022;30(9):811-831. doi:10.1080/1061186X.2022.2049011.
2. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2021;20(2):29-42. doi:10.1038/s41563-020-0715-x.
3. Moghimi SM, Hunter AC, Chernomordik LV. Nanomedicines: a major challenge in nanotoxicology and drug delivery. Nanomedicine. 2020;15(16):1547-1562. doi:10.2217/nnm.20.4.
4. Yang S, Pang Z, Zhang Y, et al. Targeted drug delivery to tumors via engineered nanoparticles: challenges and prospects. J Nanobiotechnol. 2022;20(1):112-129. doi:10.1186/s12951-022-01555-9.
5. Patel J, Parekh R, Desai J. Recent advances in the role of nanotechnology in targeted drug delivery for cancer therapy. Int J Pharm. 2020;588:119694. doi:10.1016/j.ijpharm.2020.119694.
6. Zhang J, Zhang P, Zeng X, et al. Nanoparticle-mediated drug delivery for cancer immunotherapy: challenges and future perspectives. Nanoscale. 2020;12(30):16022-16036. doi:10.1039/d0nr02592f. Tiwari G, Tiwari R,
7. Makkar S, et al. Nanocarriers in drug delivery: applications and development. J Control Release. 2023;340:129-146. doi:10.1016/j.jconrel.2023.01.013.
8. Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and cancer therapy: from principles to applications. Cancer Nanotechnol. 2022;31(1):69-95. doi:10.1016/j.cancer.2022.01.012.
9. Sheikholeslami S, Housman K, Matin M, et al. Advances in nanotechnology-based drug delivery systems in cancer treatment. Adv Drug Deliv Rev. 2019;146:93-110. doi:10.1016/j.addr.2019.01.014.
10. Lu Y, Sangeetha S, Liu Y, et al. Design and development of smart nanocarriers for targeted drug delivery. Nanomaterials. 2020;10(7):1397. doi:10.3390/nano10071397.
11. Verma A, Mahato R, Rathi P, et al. Recent advances in drug delivery using nanoparticles. J Drug Target. 2022;30(10):930-950. doi:10.1080/1061186X.2022.2067543.
12. Wang C, Yang L, Li M, et al. Targeted drug delivery in cancer therapy via nanocarriers. J Pharmacol Exp Ther. 2021;378(3):466-479. doi:10.1124/jpet.120.268991.
13. Kanjanapratum S, Vorakulpipat C, Puttipipatkhachorn S, et al. Advances in liposomal nanocarriers for the delivery of chemotherapeutic agents. Drug Deliv. 2021;28(1):149-163. doi:10.1080/10717544.2021.1854969.
14. Dey A, Sarker B, Bose S. Drug delivery strategies for cancer therapy: current advancements and future directions. J Pharm Sci. 2021;110(4):1480-1495. doi:10.1016/j.xphs.2021.01.023.
15. Zhang Z, Li N, Gao X, et al. Nanotechnology in targeted drug delivery and cancer therapy. Nanomedicine. 2021;16(15):1535-1550. doi:10.2217/nnm-2020-0360.
16. Koo S, Lee S, Lee H, et al. Recent trends in nanomedicine for cancer therapy. Biochim Biophys Acta. 2020;1865(1):202-218. doi:10.1016/j.bbcan.2019.11.003.

17. Liu T, Zhang Y, Zhang X, et al. Functionalized nanoparticles for enhanced drug delivery: applications in cancer therapy. Nanomedicine. 2019;14(3):527-539. doi:10.2217/nnm-2018-0167.
18. Mahalingam S, Gokulakrishnan S, Mohan R. Targeted drug delivery systems using nano-carriers: recent advances and applications. J Control Release. 2019;302:81-95. doi:10.1016/j.jconrel.2019.04.029.
19. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2018;13:2491-2506. doi:10.2147/IJN.S162289.
20. Almeida AJ, Simoes S, Figueiredo P, et al. Nanocarriers in drug delivery: the challenge of controlled release in a multi-dimensional approach. Nanomedicine. 2019;14(2):155-174. doi:10.2217/nnm-2018-0103.
21. Hossain MA, Zaman R, Haque MF, et al. Advances in polymeric nanocarriers for targeted drug delivery in cancer therapy. J Nanobiotechnol. 2020;18(1):16-39. doi:10.1186/s12951-020-0580-x.
22. Kim J, Lee S, Lim Y, et al. Nanoparticles for targeted drug delivery: implications in cancer treatment. J Nanosci Nanotechnol. 2020;20(2):1255-1269. doi:10.1166/jnn.2020.18311.
23. Kang C, Kim J, Lee H, et al. Advances in the design and application of nanocarriers for targeted drug delivery in cancer therapy. Nanotechnology. 2021;32(12):115702. doi:10.1088/1361-6528/abde79.
24. Choi KY, Kim G, Kim KS, et al. Recent advances in targeted drug delivery using nanoparticles for cancer therapy. J Pharm Investig. 2020;50(3):263-281. doi:10.1007/s40005-019-00400-2.
25. Raza K, Awasthi R, Raghav R, et al. Nanoparticles in drug delivery: current applications and future directions. J Drug Target. 2021;29(4):314-327. doi:10.1080/1061186X.2020.1800131.
26. Rajendran R, Ramesh R, Manogaran P, et al. Recent advances in nanotechnology-based drug delivery systems in cancer treatment. Cancer Nanotechnol. 2020;5(1):23-37. doi:10.1016/j.cancer.2020.02.010.
27. Farghali H, Alyammahi S, Al Ghamdi S, et al. Recent advances in nanomedicine for cancer therapy: a review. Biomed Pharmacother. 2020;130:110541. doi:10.1016/j.biopha.2020.110541.
28. Jeong Y, Kim J, Park K, et al. Nanoparticle-based drug delivery systems in cancer therapy. J Control Release. 2022;322:139-151. doi:10.1016/j.jconrel.2022.02.021.
29. He F, Xiao Y, Dong J, et al. Nanoparticle-based drug delivery strategies for targeted cancer therapy. Front Pharmacol. 2019;10:778. doi:10.3389/fphar.2019.00778.
30. Hussain A, Abourehab M, Zaki NM. Role of nanoparticles in cancer drug delivery. Int J Nanomedicine. 2021;16:1469-1489. doi:10.2147/IJN.S305217.
31. Martins M, Silva A, Loureiro J, et al. Nanoparticles in cancer immunotherapy: challenges and clinical applications. Pharmacol Ther. 2021;227:107870. doi:10.1016/j.pharmthera.2021.107870.
32. Alsaab H, Ali S, Ma X, et al. Nanoparticle-based targeted drug delivery for cancer therapy. Theranostics. 2020;10(8):3191-3212. doi:10.7150/thno.42315.

33. Zhang H, Zhuang Y, Li J, et al. Nanocarriers for cancer targeted drug delivery. Biomater Sci. 2020;8(12):3316-3327. doi:10.1039/d0bm01044f.
34. Cati G, Triolo D, Pappalardo M. Nanoparticle-based drug delivery systems for targeted cancer therapy. J Cancer Res Clin Oncol. 2022;148(5):1241-1255. doi:10.1007/s00432-022-03652-1.
35. Shi Y, Dong S, Zhang Y, et al. Advances in nanocarrier-based drug delivery systems for cancer therapy. Acta Pharm Sin B. 2022;12(4):1215-1233. doi:10.1016/j.apsb.2022.02.017.
36. Choi J, Kim H, Han M, et al. Nanoformulations for drug delivery in treating Alzheimer's disease: recent advances and future perspectives. Front Pharmacol. 2020;11:752. doi:10.3389/fphar.2020.00752.
37. Rodriguez-Otero N, Ricordel I, Araneda J, et al. Novel approaches in drug delivery for Alzheimer's disease using nanotechnology. Adv Drug Deliv Rev. 2021;173:51-71. doi:10.1016/j.addr.2021.04.001.
38. Zhang L, Zeng Y, Yin W, et al. Nanoparticle-based drug delivery for treatment of central nervous system diseases. Curr Drug Targets. 2020;21(14):1414-1427. doi:10.2174/1389450120666201109154935.
39. Lee J, Lee M, Kim J, et al. Nanoparticle-based drug delivery systems for brain cancer treatment. Nanomaterials. 2020;10(11):2100. doi:10.3390/nano10112100.
40. Wang J, Yang H, Zhang Z, et al. Nanoparticle-based drug delivery systems for the treatment of neurological disorders. Nanomedicine. 2020;15(12):1399-1413. doi:10.2217/nnm-2020-0224.
41. Shah N, Mehta V, Liu G, et al. Nanoparticle-based approaches for the delivery of anti-cancer agents. Cancer Nanotechnol. 2022;16(1):4-20. doi:10.1016/j.cancer.2021.09.019.
42. Bou Khalil M, Sharif A, Junaid A, et al. Nanoparticles in the treatment of infectious diseases. J Control Release. 2021;332:470-490. doi:10.1016/j.jconrel.2021.02.015.
43. Ramesh R, Jayakumar S, Pooja V, et al. Nanomedicine for the treatment of infections: current and future perspectives. Nanomedicine. 2021;16(10):1049-1065. doi:10.2217/nnm-2021-0146.
44. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2019;143:1-22. doi:10.1016/j.addr.2019.03.003.
45. Zhang Y, Lee J, Liu H, et al. Nanoparticles as drug delivery systems for targeted cancer therapy. Nanotechnology. 2021;32(3):31001. doi:10.1088/1361-6528/abc5d8.
46. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2022;64(4):1405-1424. doi:10.1016/j.addr.2022.02.013.
47. Naskar S, Bhuniya S, Pathak K, et al. Functionalized nanocarriers for targeted drug delivery: recent trends in cancer treatment. Chem Commun. 2020;56(44):5984-5994. doi:10.1039/d0cc03251a.
48. Goh K, Tan S, Ang C, et al. Advances in nanocarriers for targeted drug delivery in cancer immunotherapy. Biomaterials. 2021;274:120846. doi:10.1016/j.biomaterials.2021.120846.
49. Huang P, Zhang X, Chen X. Nanoparticle-based drug delivery for the treatment of cancer. Nanomedicine. 2021;16(1):123-135. doi:10.2217/nnm-2020-0161.

50. Pala A, Shinde S, Reddy N. Recent advancements in targeted drug delivery using nanotechnology in oncology. Theranostics. 2021;11(2):1182-1201. doi:10.7150/thno.50240.
51. Bae Y, Park K. Targeted drug delivery to tumors: myths, reality, and possibility. J Control Release. 2019;153(3):315-326. doi:10.1016/j.jconrel.2019.04.019.
52. Zhang Y, Ding S, Liu S, et al. Recent advances in nanoparticle-based drug delivery for cancer therapy. Int J Pharm. 2020;593(1):161-170. doi:10.1016/j.ijpharm.2020.03.022.
53. Ahmadi S, Shadloo M, Moghadam A, et al. Polymeric nanoparticles for the treatment of cancer: recent advances in drug delivery. Nanomedicine. 2019;14(10):1073-1095. doi:10.2217/nnm-2019-0123.
54. Siddique R, Garg R, Ramasamy T, et al. Nanocarriers for enhanced drug delivery in cancer treatment. Nanomedicine. 2020;15(6):787-803. doi:10.2217/nnm-2020-0246.
55. Wang Y, Zhang Y, Gao H, et al. Recent advances in polymeric nanoparticles for targeted cancer drug delivery. Nanomedicine. 2020;15(7):1261-1284. doi:10.2217/nnm-2020-0213.
56. Yang C, Chen X, Li Q, et al. Nanomedicine in targeted drug delivery: recent advances and challenges. Nanotechnol Rev. 2021;10(1):43-58. doi:10.1515/ntrev-2020-0056.
57. Rahman Z, Imran M, Khalid A, et al. Recent advances in nanocarriers for drug delivery in cancer therapy. Pharmaceutics. 2020;12(4):302. doi:10.3390/pharmaceutics12040302.
58. Mao L, Zeng F, Liu Q, et al. Smart nanocarriers for cancer therapy: advances and future perspectives. Nanoscale. 2021;13(2):594-612. doi:10.1039/d0nr07491f.
59. Bassi R, Jain A, Shankar G. Advances in nanoparticle-based drug delivery systems: from basic principles to clinical applications. J Control Release. 2022;330:153-167. doi:10.1016/j.jconrel.2022.02.020.
60. Jain S, Lee S, Kim H, et al. Recent advances in nanoparticles for drug delivery applications. J Nanobiotechnol. 2021;19(1):35-50. doi:10.1186/s12951-021-01048-7.
61. Zhang L, Xu C, Shen Y, et al. Nanomedicine for targeted delivery in cancer therapy: From basic research to clinical applications. J Control Release. 2023;358:514-533. doi:10.1016/j.jconrel.2023.04.018.
62. Lee J, Lee M, Han H, et al. Targeted drug delivery using functionalized nanomaterials: Advances in the treatment of cancer and other diseases. J Nanomater. 2021;2021:8965331. doi:10.1155/2021/8965331.
63. Silva F, Ribeiro C, da Silva M, et al. Recent developments in nanocarrier systems for targeted cancer therapy. Expert Opin Drug Deliv. 2022;19(4):411-430. doi:10.1080/17425247.2022.2082323.
64. Wang W, Li J, Li X, et al. Lipid-based nanocarriers for targeted drug delivery: A comprehensive review. J Drug Target. 2022;30(7):633-652. doi:10.1080/1061186X.2022.2048799.
65. Yu M, Zhang L, Zhao Z, et al. Nanoparticles for targeted drug delivery in neurological disorders. Neurotherapeutics. 2021;18(3):2130-2148. doi:10.1007/s13311-021-00973-0.
66. Zhang Y, Liu Y, Liu X, et al. Targeted delivery of chemotherapeutic agents using nanocarriers: Advances and challenges. Front Pharmacol. 2021;12:711309. doi:10.3389/fphar.2021.711309.

67. Kim J, Cho H, Jung Y, et al. Multifunctional nanocarriers for drug delivery in the treatment of brain tumors. Int J Nanomedicine. 2021;16:4161-4179. doi:10.2147/IJN.S320202.
68. Raj R, Ahuja A, Narayan R, et al. Nanotechnology in cancer therapy: A review of recent progress. Front Oncol. 2021;11:646232. doi:10.3389/fonc.2021.646232.
69. Maleki A, Shahin H, Kharaziha M, et al. Nanomedicine-based approaches for targeting solid tumors: Current status and future perspectives. Cancers. 2021;13(17):4326. doi:10.3390/cancers13174326.
70. Choi Y, Park J, Lee H, et al. Recent advances in stimuli-responsive nanocarriers for cancer therapy. J Mater Chem B. 2020;8(17):3815-3830. doi:10.1039/d0tb00281c.
71. O'Rourke P, Kohli G, Gupta K, et al. A review on nanomaterial-based drug delivery systems for cancer therapy. Nanomaterials. 2021;11(5):1106. doi:10.3390/nano11051106.
72. Xu L, Wang D, Gu Y, et al. Nanocarriers for the treatment of bacterial infections: Targeting strategies and applications. Adv Drug Deliv Rev. 2020;157:11-22. doi:10.1016/j.addr.2020.07.001.
73. Wong P, Hwang D, Chen Y, et al. Nanoparticle-based drug delivery for cancer therapy: An update. Nanomedicine. 2022;17(5):415-428. doi:10.2217/nnm-2021-0478.
74. Li Y, Ma M, Sun X, et al. Recent advances in the application of nanocarriers for the treatment of diabetes. Nanomedicine. 2020;15(19):1805-1821. doi:10.2217/nnm-2020-0304.
75. Kumar P, Patel S, Sharma S, et al. Functionalized nanoparticles for targeted drug delivery in cancer therapy. Nanoscale Res Lett. 2021;16(1):45. doi:10.1186/s11671-021-03575-6.
76. Patel V, Goel A, Kapoor S, et al. Polymeric nanoparticles for targeted drug delivery: Design, fabrication, and applications. Mater Sci Eng C. 2020;113:110989. doi:10.1016/j.msec.2020.110989.
77. Ali A, Anwar S, Sandeep B, et al. Targeted nanoparticles for drug delivery in lung cancer therapy: An updated review. Nanomaterials. 2021;11(10):2557. doi:10.3390/nano11102557.
78. Choi W, Lee S, Kim J, et al. Nano-based drug delivery systems for the treatment of inflammatory diseases: Recent advances and future perspectives. J Control Release. 2021;338:428-447. doi:10.1016/j.jconrel.2021.07.027.
79. Zhang Y, Wu W, Chen X, et al. Smart nanomaterials for controlled and targeted drug delivery. J Mater Chem B. 2020;8(16):3391-3405. doi:10.1039/d0tb00498c.
80. Shukla R, Verma A, Joshi N, et al. Targeted drug delivery systems in the treatment of autoimmune diseases: A review. Biol Pharm Bull. 2021;44(2):221-237. doi:10.1248/bpb.b20-00875.
81. Zhang F, Yang S, Liu L, et al. Recent advances in nanomaterial-based targeted delivery strategies for cardiovascular diseases. J Mater Chem B. 2020;8(3):450-469. doi:10.1039/c9tb02458b.
82. Kesharwani P, Jain K, Agrawal S, et al. Dendrimer-based drug delivery systems: An overview. Biol Pharm Bull. 2020;43(1):1-9. doi:10.1248/bpb.b19-00635.

83. Wei L, Wu X, Feng T, et al. Nanomedicine in the treatment of neurodegenerative diseases: Recent advances and future perspectives. Front Pharmacol. 2021;12:642581. doi:10.3389/fphar.2021.642581.
84. Hussain R, Khokhar N, Tan Y, et al. Role of nanocarriers in the targeted drug delivery for the treatment of ocular diseases. Pharmaceutics. 2021;13(8):1160. doi:10.3390/pharmaceutics13081160.
85. Zhang L, Zhang S, Song W, et al. Lipid-based nanoparticles for targeted drug delivery in cancer therapy: A comprehensive review. J Drug Target. 2021;29(3):243-258. doi:10.1080/1061186X.2021.1874703.
86. Farokhzad O, Langer R. Nanomedicine: Developing smarter therapeutic systems. Adv Drug Deliv Rev. 2021;160:1-13. doi:10.1016/j.addr.2020.07.007.
87. Yu L, Zhang W, Ma C, et al. Nanoparticle-based drug delivery systems for targeted cancer therapy. Nanomedicine. 2020;15(15):1373-1390. doi:10.2217/nnm-2020-0366.
88. Anwar S, Ali M, Baig M, et al. Recent trends in nanotechnology-based drug delivery systems for cancer treatment. Crit Rev Ther Drug Carrier Syst. 2021;38(2):175-208. doi:10.1615/CritRevTherDrugCarrierSyst.2020036451.
89. Patra J, Choi Y, Hong C, et al. Nanotechnology in the treatment of infectious diseases: From laboratory research to clinical application. Nanomedicine. 2021;16(11):890-907. doi:10.2217/nnm-2021-0101.
90. Singh S, Kumar M, Garg S, et al. Targeted drug delivery in cancer: Recent advances and challenges. Crit Rev Oncol Hematol. 2020;151:102970. doi:10.1016/j.critrevonc.2020.102970.